Mediatorn, solution for injections 15 mg/ml, 1ml x 10 ampoules — Made in Ukraine — Free Delivery

Brand: ARTERIUM
Product Code: Mediatorn
Availability: In Stock

$38.05

Description

Product description

Pharmacological properties

Pharmacodynamics. The mediator has a direct stimulating effect on the conduction of an impulse along nerve fibers, interneuronal and neuromuscular synapses of the peripheral and central nervous system.

The pharmacological action of Mediatorn is based on a combination of two mechanisms of action:

blockade of potassium channels in the membrane of neurons and muscle cells;
reversible inhibition of cholinesterase in synapses.

Mediatorn enhances the effect on smooth muscles not only of acetylcholine, but also of adrenaline, serotonin, histamine and oxytocin.

The mediatorn exhibits the following pharmacological effects:

improves and stimulates impulse conduction in the nervous system and neuromuscular transmission;
enhances the contractility of smooth muscle organs under the influence of all acetylcholine, adrenaline, serotonin, histamine and oxytocin receptor antagonists, with the exception of potassium chloride;
improves memory, inhibits the progradient development of dementia;
restores impulse conduction in the peripheral nervous system, disturbed as a result of various factors, such as trauma, inflammation, the action of local anesthetics, some antibiotics, potassium chloride, toxins, and the like;
specifically moderately stimulates the central nervous system with individual manifestations of a sedative effect;
shows analgesic effect;
exhibits an antiarrhythmic effect.

The preparation does not have teratogenic, embryotoxic, mutagenic, carcinogenic, allergenic and immunotoxic effects, and also does not affect the endocrine system.

Pharmacokinetics. Mediatorn is rapidly absorbed after s / c or / m administration. Cmax in the blood is reached after 25-30 minutes, 40-50% of the active substance binds to plasma proteins. The mediator quickly enters the tissues; T½ is 40 min. Metabolized in the liver. The preparation is excreted by the kidneys, as well as extrarenally (through the gastrointestinal tract). T½ for parenteral administration of the preparation is 2-3 hours. Excretion occurs mainly due to tubular secretion, and only 1/3 of the dose is excreted by glomerular filtration. With parenteral administration, 34.8% of the dose of the preparation is excreted in the urine unchanged.

Indications

Diseases of the peripheral nervous system: mono- and polyneuropathy, polyradiculopathy, myasthenia gravis and myasthenic syndrome of various etiologies.

Diseases of the central nervous system: bulbar paralysis and paresis; the recovery period of organic lesions of the central nervous system, accompanied by motor disorders.

Application

Injection solution to be administered intramuscularly or s / c. the dose and duration of treatment should be determined individually depending on the severity of the disease.

Diseases of the peripheral nervous system. Mono- and polyneuropathies of various origins: s / c or / m inject 5-15 mg 1-2 times a day, the course of treatment is 10-15 days (in severe cases up to 30 days); further treatment should be continued with the oral form of ipidacrine.

Myasthenia gravis and myasthenic syndrome: s / c or / m inject 5-30 mg 1-3 times a day, and then switch to a tablet form. The general course of treatment is 1-2 months. If necessary, treatment can be repeated several times with a break between courses of 1-2 months.

CNS diseases. Bulbar paralysis and paresis: s / c and / m to enter 5-15 mg 1-2 times a day, the course of treatment is 10-15 days, if possible, switch to a tablet form.

The recovery period for organic lesions of the central nervous system: 10-15 mg 1-2 times a day, the course of treatment is up to 15 days.

Contraindications

Hypersensitivity to ipidacrine.
Epilepsy.
Extrapyramidal disorders with hyperkinesis.
Angina.
Severe bradycardia.
Bronchial asthma.
vestibular disorders.
Mechanical obstruction of the intestines and urinary tract.
An ulcer of the stomach or duodenum in the acute stage.
During pregnancy and breastfeeding.

Side effects

Mediatorn, like all medicines, can cause side effects, although not everyone gets them.

From the side of the cardiovascular system: increased heart rate, decreased heart rate.

From the nervous system: when taking high doses - dizziness, headache, drowsiness, general weakness, convulsions.

On the part of the respiratory system: increased separation of bronchial secretions, bronchospasm.

From the digestive system: increased salivation, nausea; when using high doses - vomiting, diarrhea, jaundice, chest pain.

From the side of the skin and subcutaneous tissues: increased sweating; allergic reactions, including rash, itching, urticaria, angioedema.

From the reproductive system: increased tone of the uterus.

Others: changes at the injection site.

In case of development of undesirable side effects, the dose should be reduced or the use of the preparation should be interrupted for a short time (for 1-2 days). Salivation and a decrease in heart rate can be reduced with the help of M-anticholinergics (atropine, etc.).

special instructions

Use with caution in patients with a history of gastric and duodenal ulcers, respiratory diseases, including acute respiratory diseases, diseases of the cardiovascular system that are not associated with coronary pain, with thyrotoxicosis.

Use during pregnancy and lactation. Mediatorn increases the tone of the uterus and can cause premature birth, so during pregnancy, the use of the preparation is contraindicated. During lactation, the use of the preparation is contraindicated.

Children. There are no systematized data on the use of the parenteral form of ipidacrine in children (under the age of 18 years), so the preparation is not used in children.

The ability to influence the reaction rate when driving vehicles or other mechanisms. During the period of treatment, it is necessary to refrain from driving a car, as well as from potentially hazardous activities that require an increased concentration of attention and speed of psychomotor reactions.

Interactions

Mediatorn enhances the sedative effect in combination with preparations that suppress the central nervous system. action and side effects are enhanced when combined with other cholinesterase inhibitors and m-cholinomimetic agents. in patients with myasthenia gravis, the risk of developing a "cholinergic" crisis increases if the mediator is used simultaneously with cholinergic agents. the risk of developing bradycardia increases if β-adrenergic blockers were used before treatment with mediatorn. mediatorn can be used in combination with nootropic preparations. alcohol enhances the side effects of the preparation.

Overdose

Symptoms: bronchospasm, lacrimation, increased sweating, pupillary constriction, nystagmus, increased gastrointestinal motility, spontaneous defecation and urination, vomiting, jaundice, bradycardia, impaired intracardiac conduction, arrhythmias, decreased blood pressure, anxiety, anxiety, agitation, fear, ataxia, convulsions, coma, speech disorder, drowsiness, general weakness.

Treatment: symptomatic therapy should be carried out, M-anticholinergics should be used: atropine, cyclodol, metacin, etc.

Storage conditions

In original packaging at a temperature not exceeding 25 ° C.

0 reviews

There are no reviews for this product.